CM
ARIA

Castleark Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Castleark Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-285,055
Closed -$3.9M – 442
2016
Q3 		$3.9M Buy
+285,055
New +$2.86M 0.12% 201

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Castleark Management's ARIA Position: Q4 2016 in Review

Castleark Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 285,055 shares — an estimated $3.9M sold.

Castleark Management first reported a position in ARIA in Q3 2016 and held it in 1 quarter. The position peaked at $3.9M in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Castleark Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Castleark Management sold 285,055 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $3.9M.
  • Castleark Management first reported a position in Ariad Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • Castleark Management's Ariad Pharmaceuticals Inc position peaked at $3.9M in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Castleark Management's 13F filing for Q4 2016, filed 15 Feb 2017.